文献速递其他结缔组织病

聚乙二醇化腺苷脱氨酶在系统性硬化症临床前模型中改善炎症、血管病变与纤维化

Recombinant Adenosine Deaminase Ameliorates Inflammation, Vascular Disease, and Fibrosis in Preclinical Models of Systemic Sclerosis.
PubMed 文献 · Arthritis Rheumatol · 2020-06-25

本研究在Fra-2小鼠和硬皮病慢性GVHD小鼠模型中评估PEG-ADA的治疗效果,并在人全层皮肤模型中体外验证。PEG-ADA抑制肌成纤维细胞分化,减轻肺、皮肤和肠道纤维化,改善炎症和血管病变,且所用剂量具有药理学相关性且耐受良好。

要点

  • PEG-ADA在两种SSc临床前模型中减轻纤维化、炎症和血管病变。
  • PEG-ADA已获FDA批准用于ADA缺陷型重症联合免疫缺陷病,具有转化潜力。
  • 体外人全层皮肤模型验证了PEG-ADA的抗纤维化作用。

核心结论

  • PEG-ADA在药理学相关且耐受良好的剂量下改善SSc的三大核心特征:纤维化、血管病变和炎症。

研究设计与样本

  • 在Fra-2小鼠和B10.D2→BALB/c(H-2d)硬皮病慢性GVHD模型中分析PEG-ADA对炎症、血管重塑和组织纤维化的影响。
  • 在体外人全层皮肤模型中确认PEG-ADA的效果。

主要发现

  • 在Fra-2小鼠中,PEG-ADA使肺纤维化减少34.3%(P=0.0079;n=6),皮肤纤维化减少51.8%(P=0.0006;n=6),肠道纤维化减少17.7%(P=0.0228;n=6)。
  • 在硬皮病慢性GVHD模型中,PEG-ADA使纤维化减少38.4%(P=0.0063;n=8)。
  • PEG-ADA减少炎症并纠正M2/Th2/2型固有淋巴细胞2偏倚。
  • PEG-ADA使肺血管平滑肌细胞增殖减少40.5%(P<0.0001;n=6),血管壁增厚减少39.6%(P=0.0028;n=6),肺动脉闭塞减少63.9%(P=0.0147;n=6)。
  • PEG-ADA使微血管内皮细胞凋亡减少65.4%(P=0.0001;n=6),毛细血管稀疏减少32.5%(P=0.0199;n=6)。

临床怎么用

  • PEG-ADA已获FDA批准用于ADA缺陷型重症联合免疫缺陷病,可能具有直接的转化意义。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Systemic sclerosis (SSc) is characterized by fibrosis, vascular disease, and inflammation. Adenosine signaling plays a central role in fibroblast activation. We undertook this study to evaluate the therapeutic effects of adenosine depletion with PEGylated adenosine deaminase (PEG-ADA) in preclinical models of SSc. METHODS: The effects of PEG-ADA on inflammation, vascular remodeling, and tissue fibrosis were analyzed in Fra-2 mice and in a B10.D2→BALB/c (H-2d ) model of sclerodermatous chronic graft-versus-host disease (GVHD). The effects of PEG-ADA were confirmed in vitro in a human full-thickness skin model. RESULTS: PEG-ADA effectively inhibited myofibroblast differentiation and reduced pulmonary fibrosis by 34.3% (with decreased collagen expression) (P = 0.0079; n = 6), dermal fibrosis by 51.8% (P = 0.0006; n = 6), and intestinal fibrosis by 17.7% (P = 0.0228; n = 6) in Fra-2 mice. Antifibrotic effects of PEG-ADA were also demonstrated in sclerodermatous chronic GVHD (reduced by 38.4%) (P = 0.0063; n = 8), and in a human full-thickness skin model. PEG-ADA treatment decreased inflammation and corrected the M2/Th2/group 2 innate lymphoid cell 2 bias. Moreover, PEG-ADA inhibited proliferation of pulmonary vascular smooth muscle cells (reduced by 40.5%) (P < 0.0001; n = 6), and prevented thickening of the vessel walls (reduced by 39.6%) (P = 0.0028; n = 6) and occlusions of pulmonary arteries (reduced by 63.9%) (P = 0.0147; n = 6). Treatment with PEG-ADA inhibited apoptosis of microvascular endothelial cells (reduced by 65.4%) (P = 0.0001; n = 6) and blunted the capillary rarefication (reduced by 32.5%) (P = 0.0199; n = 6). RNA sequencing demonstrated that treatment with PEG-ADA normalized multiple pathways related to fibrosis, vasculopathy, and inflammation in Fra-2 mice. CONCLUSION: Treatment with PEG-ADA ameliorates the 3 cardinal features of SSc in pharmacologically relevant and well-tolerated doses. These findings may have direct translational implications, as PEG-ADA has already been approved by the Food and Drug Administration for the treatment of patients with ADA-deficient severe combined immunodeficiency disease.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Zhang Y, Zhu H, Layritz F, et al. Recombinant Adenosine Deaminase Ameliorates Inflammation, Vascular Disease, and Fibrosis in Preclinical Models of Systemic Sclerosis. Arthritis Rheumatol. 2020. PMID: 32182396. doi:10.1002/art.41259

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。